Inventor · disambiguated record
Michael R. Schlabach
Also filed as: SCHLABACH JR MICHAEL · SCHLABACH JR MICHAEL RAY · SCHLABACH MICHAEL · SCHLABACH MICHAEL R
16 granted patents·16 pending applications·37 citations·filing 2009–2025
91Inventor score
Files withKSQ THERAPEUTICS INC23ARROWHEAD PHARMACEUTICALS INC3NOVARTIS AG3ARROWHEAD RES CORP1BRIGHAM & WOMENS HOSPITAL1
Top patents by PatentIndex Score
32 records- 0196US11608500B2Gene-regulating compositions and methods for improved immunotherapyKSQ THERAPEUTICS INC·Filed 2022·Granted Mar 21, 2023·5 cites·20 claims
- 0295US11459544B2Gene-regulating compositions and methods for improved immunotherapyKSQ THERAPEUTICS INC·Filed 2022·Granted Oct 4, 2022·4 cites·20 claims
- 0395US11111493B2Gene-regulating compositions and methods for improved immunotherapyKSQ THERAPEUTICS INC·Filed 2020·Granted Sep 7, 2021·5 cites·21 claims
- 0494US11421228B2Gene-regulating compositions and methods for improved immunotherapyKSQ THERAPEUTICS INC·Filed 2021·Granted Aug 23, 2022·3 cites·16 claims
- 0594US11332713B2Gene-regulating compositions and methods for improved immunotherapyKSQ THERAPEUTICS INC·Filed 2020·Granted May 17, 2022·5 cites·45 claims
- 0694US11261428B2Gene-regulating compositions and methods for improved immunotherapyKSQ THERAPEUTICS INC·Filed 2019·Granted Mar 1, 2022·7 cites·24 claims
- 0793US12084682B2Gene-regulating compositions and methods for improved immunotherapyKSQ THERAPEUTICS INC·Filed 2022·Granted Sep 10, 2024·1 cites·7 claims
- 0891US12123021B2Gene-regulating compositions and methods for improved immunotherapyKSQ THERAPEUTICS INC·Filed 2022·Granted Oct 22, 2024·1 cites·12 claims
- 0988US12280111B2Gene-regulating compositions and methods for improved immunotherapyKSQ THERAPEUTICS INC·Filed 2024·Granted Apr 22, 2025·0 cites·20 claims
- 1086US11078483B1Methods for measuring and improving CRISPR reagent functionKSQ THERAPEUTICS INC·Filed 2017·Granted Aug 3, 2021·3 cites·22 claims
- 1183US11530413B2Compositions and methods to treat cancerNOVARTIS AG·Filed 2018·Granted Dec 20, 2022·3 cites·6 claims
- 1283US2025270555A1Organic compositions to treat beta-catenin-related diseasesARROWHEAD PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1379US2023220380A1Gene-regulating compositions and methods for improved immunotherapyKSQ THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1476US2025101435A1Compositions and methods to treat cancerNOVARTIS AG·Filed 2024·Application pending·0 cites
- 1576US2025195577A1Gene-regulating compositions and methods for improved immunotherapyKSQ THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1670US2019284553A1Gene-regulating compositions and methods for improved immunotherapyKSQ THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 1770US2024052354A1Compositions and methods to treat cancerNOVARTIS AG·Filed 2022·Application pending·0 cites
- 1868US2023088186A1Gene-regulating compositions and methods for improved immunotherapyKSQ THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1965US11787813B2Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitorsKSQ THERAPEUTICS INC·Filed 2022·Granted Oct 17, 2023·0 cites·30 claims
- 2064US11946163B2Methods for measuring and improving CRISPR reagent functionKSQ THERAPEUTICS INC·Filed 2021·Granted Apr 2, 2024·0 cites·7 claims
- 2162US11485736B2Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitorsKSQ THERAPEUTICS INC·Filed 2019·Granted Nov 1, 2022·0 cites·45 claims
- 2261US12188045B2Guide RNA combinations and methods of useKSQ THERAPEUTICS INC·Filed 2022·Granted Jan 7, 2025·0 cites·18 claims
- 2357US2019284529A1Gene-regulating compositions and methods for improved immunotherapyKSQ THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2455US2018282728A1Organic compositions to treat beta-catenin-related diseasesARROWHEAD PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 2554US2025130220A1Lymphocyte potency assayKSQ THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2653US2024376428A1Methods for activation and expansion of tumor infiltrating lymphocytesKSQ THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2752US10023862B2Organic compositions to treat beta-catenin-related diseasesHUESKEN DIETER·Filed 2013·Granted Jul 17, 2018·0 cites·9 claims
- 2850US2011081362A1Treatment of cancerBRIGHAM & WOMENS HOSPITAL·Filed 2009·Application pending·0 cites
- 2950US2023108584A1Methods for activation and expansion of tumor infiltrating lymphocytesKSQ THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3049US2015238515A1Organic compositions to treat kras-related diseasesARROWHEAD RES CORP·Filed 2013·Application pending·0 cites
- 3148US2020347386A1Combination gene targets for improved immunotherapyKSQ THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3245US2018153919A1Organic compositions to treat kras-related diseasesARROWHEAD PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Michael R. Schlabach files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →